OpenLegislation

Regulation 24 Relocations that do not result in significant change to pharmaceutical services provision

United Kingdom

(1)

Section 129(2A) of the 2006 Act (regulations as to pharmaceutical services) does not apply to an application from a person already included in a pharmaceutical list to relocate to different premises in the area of the relevant HWB (HWB1) if—

(a)

for the patient groups that are accustomed to accessing pharmaceutical services at F1or from the existing premises, the location of the new premises is not significantly less accessible;

(b)

in the opinion of F2NHS England, granting the application would not result in a significant change to the arrangements that are in place for the provision of local pharmaceutical services or of pharmaceutical services other than those provided by a person on a dispensing doctor list—

(i)

in any part of the area of HWB1, or

(ii)

in a controlled locality in the area of a neighbouring HWB, where that controlled locality is within 1.6 kilometres of the premises to which the applicant is seeking to relocate;

(c)

NHS England F3is not of the opinion that granting the application would cause significant detriment to proper planning in respect of the provision of pharmaceutical services in the area of HWB1;

(d)

the services the applicant undertakes to provide at F4or from the new premises are the same as the services the applicant has been providing at F5or from the existing premises (whether or not, in the case of enhanced services, NHS England chooses to commission them); and

(e)

the provision of pharmaceutical services will not be interrupted (except for such period as NHS England may for good cause allow).

(2)

Section 129(2A) of the 2006 Act does not apply to an application from a person already included in a pharmaceutical list for the area of a HWB (HWB2) for inclusion in the pharmaceutical list for the area of a neighbouring HWB (HWB3), or inclusion in the pharmaceutical list for the area of HWB3 also in respect of other premises than those already listed in relation to that person, if—

(a)

the purpose of the application is to relocate to different premises;

(b)

for the patient groups that are accustomed to accessing pharmaceutical services at F6or from the existing premises (P1), the location of the new premises (P2) is not significantly less accessible;

(c)

in the opinion of NHS England, granting the application would not result in a significant change to the arrangements that are in place for the provision of local pharmaceutical services or of pharmaceutical services other than those provided by a person on a dispensing doctor list—

(i)

in any part of HWB3's area; or

(ii)

in a controlled locality in the area of a neighbouring HWB (including HWB2), where that controlled locality is within 1.6 kilometres of P2;

(d)

NHS England F7is not of the opinion that granting the application would cause significant detriment to proper planning in respect of the provision of pharmaceutical services in the area of HWB3;

(e)

the services the applicant undertakes to provide at F8or from P2 are the same as the services the applicant has been providing at F9or from P1 (whether or not, in the case of enhanced services, NHS England chooses to commission them);

(f)

the provision of pharmaceutical services will not be interrupted (except for such period as NHS England may for good cause allow); and

(g)

the applicant consents to—

(i)

where the applicant has only one set of listed chemist premises in the pharmaceutical list for the area of HWB2, the removal of the applicant's name from that pharmaceutical list, or

(ii)

where the applicant has more than one set of listed chemist premises in the pharmaceutical list for the area of HWB2, the removal of P1 from being listed in relation to the applicant in that pharmaceutical list,

with effect from the date on which the applicant undertakes to provide pharmaceutical services from P2.

(3)

An application pursuant to this regulation must be refused if the existing pharmacy premises from which the applicant is seeking to relocate (P3)—

(a)

were listed in relation to an NHS pharmacist as a result of an application to which regulation 13(1)(a) of the 2005 Regulations M1 (exemption from the necessary or expedient test) applied, and—

(i)

P3 are located in an area that, immediately before the 2012 Regulations came into force, was an approved retail area (within the meaning given in regulation 15 of the 2005 Regulations (approved retail areas)), and

(ii)

the applicant proposes to relocate from P3 to premises that are outside that area;

(b)

were listed in relation to an NHS pharmacist as a result of an application to which regulation 13(1)(c) of the 2005 Regulations applied, unless—

(i)

the provider, or where there is more than one provider all the providers, of primary medical services at the one-stop primary care centre (within the meaning given in regulation 16 of the 2005 Regulations M2 (new one-stop primary care centres)) at which P3 are located are relocating with the applicant to a new discrete site or building,

(ii)

at F10or from that new discrete site or building primary medical services are or are to be provided by one or more providers of primary medical services with a patient list of, or patient lists with a combined total of, 18,000 patients, and

(iii)

at F11or from that site or building the services of a broad range of health care professionals are or will be regularly and frequently provided (together, where appropriate, with other health or social services); F12...

(c)

have been listed in relation to the applicant for a period of less than 12 months prior to the application, and—

(i)

that listing arose out of the applicant relocating to P3 from other pharmacy premises,

(ii)

that relocation arose out of the grant of an application—

(aa)

that was an excepted application by virtue of this regulation or regulation 24 of the 2012 Regulations (relocations that do not result in significant change to pharmaceutical services provision), or

(bb)

to which regulation 6 or 7 of the 2005 Regulations M3 (which related to minor relocations) applied, and

(iii)

the applicant is unable to satisfy NHS England that relocation from P3 is necessary for reasons that NHS England accepts are good cause F13; or

F14(d)

are distance selling premises, unless—

(i)

the premises to which the applicant is seeking to relocate are also distance selling premises, and

(ii)

if the application was one to which regulation 25(1) applied, it would not be refused pursuant to regulation 25(2).

Annotations

Textual amendments

F1

Words in reg. 24(1)(a) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 19(2)(a)

F2

Words in Regulations substituted (6.11.2023) by The Health and Care Act 2022 (Further Consequential Amendments) (No. 2) Regulations 2023 (S.I. 2023/1071), reg. 1(1), Sch. para. 1

F3

Words in reg. 24(1)(c) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 8(a)

F4

Words in reg. 24(1)(d) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 19(2)(b)(i)

F5

Words in reg. 24(1)(d) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 19(2)(b)(ii)

F6

Words in reg. 24(2)(b) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 19(3)(a)

F7

Words in reg. 24(2)(d) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 8(b)

F8

Words in reg. 24(2)(e) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 19(3)(b)(i)

F9

Words in reg. 24(2)(e) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 19(3)(b)(ii)

F10

Words in reg. 24(3)(b)(ii) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 19(4)(a)

F11

Words in reg. 24(3)(b)(iii) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 19(4)(b)

F12

Word in reg. 24(3)(b) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 8(c)(i)

F13

Word in reg. 24(3)(c) inserted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 8(c)(ii)

F14

Reg. 24(3)(d) inserted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 8(c)(iii)

Marginal citations

M1

Prior to its revocation, the heading of regulation 13 was amended by S.I. 2009/2205.

M2

Prior to its revocation, regulation 16 was amended by S.I. 2005/1501.

M3

Prior to their revocation, regulations 6 and 7 were both amended by S.I. 2005/1501 and 2006/3373.